Centiva Capital, LP Arbutus Biopharma Corp Call Options Transaction History

Centiva Capital, LP

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$2.26 - $2.92 $222,835 - $287,912	98,600 Added 2738.89%	102,200 $263,000
Q4 2023 Feb 14, 2024	BUY	$1.69 - $2.54 $6,084 - $9,144	3,600 New	3,600 $9,000
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $93,268 - $138,253	29,990 Added 299900.0%	30,000 $117,000
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $26 - $46	10 New	10 $0

155

99.5M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $478M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.